Effects of neutrophil-to-lymphocyte ratio, tumor-infiltrating lymphocyte and neutrophil scores on prognosis in low-risk endometrial cancer

Background: This study aimed to determine the association of neutrophil-to-lymphocyte ratio (NLR), tumor-infiltrating lymphocyte (TIL) and tumor-infiltrating neutrophil (TIN) scores with recurrence-free survival (RFS) in patients with low-risk endometrial cancer. Methods: A total of 233 low-risk endometrial cancer patients were retrospectively screened. The NLR values calculated from the peripheral blood and TIL and TIN scores from tumor tissues were compared for survival analyses. Results: There was no statistically significant difference in RFS according to the NLR with an optimal prognostic cut-off value of 2.4. The expected RFS time was 77.9 months (±0.7, 95%Confidence Interval (CI): 76.5–79.3) for patients with an NLR <2.4 and 76.5 months (±1.3, 95% CI: 73.7–79.2) for patients with an NLR ≥2.4 (p = 0.303). The expected RFS times were 69.9 months (±2.7, 95% CI: 64.6–75.3) for patients with a TIL score of 1, 65.5 months (±1.9, 95% CI: 61.3–69.4) for patients with a TIL score of 2, and 74.5 months for patients with a TIL score of 3 (±1.9, 95% CI: 70.8–78.2), respectively.(score 1 vs. score 2, p = 0.031) (score 1 vs. score 3, p = 0.302) (score 2 vs. score 3, p = 0.018). Patients with a TIN score of 1 had a worse RFS than those with a TIN score of 0; 55.9 months (±5.3, 95% CI: 45.4–66.4), versus 78.6 months (±0.3, 95% CI: 77.9–79.3)(p < 0.001). Conclusions: A TIN score of 1 and a TIL score of 2 were associated with worse RFS in patients with low-risk endometrial cancer. No significant association was found with the NLR.

Neutrophil-to-lymphocyte ratio; Tumor-infiltrating lymphocyte; Tumor-infiltrating neutrophil; Low-risk endometrial cancer; Recurrence-free survival (RFS)

[1] Gao S, Wang J, Li Z, Wang T, Wang J. Global trends in incidence and mortality rates of endometrial cancer among individuals aged 55 years and above from 1990 to 2021: an analysis of the global burden of disease. International Journal of Women’s Health. 2025; 17: 651–662.

[2] Karkia R, Nyakunengwa TR, Uwins C, Stewart A, Patel H, Tailor A, et al. Endometrial cancer: analysing patterns of recurrence and real-life outcome data using the 2020 ESGO-ESTRO-ESP risk stratification system. Clinical Oncology. 2024; 36: 719–727.

[3] Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer. 2021; 31: 12–39.

[4] Åkesson Å, Adok C, Dahm-Kähler P. Recurrence and survival in endometrioid endometrial cancer—a population-based cohort study. Gynecologic Oncology. 2023; 168: 127–134.

[5] Ouh YT, Oh Y, Joo J, Woo JH, Han HJ, Cho HW, et al. Assessing the new 2020 ESGO/ESTRO/ESP endometrial cancer risk molecular categorization system for predicting survival and recurrence. Cancers. 2024; 16: 965.

[6] Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterisation of endometrial carcinoma. Nature. 2013; 497: 67–73.

[7] Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Annals of Oncology. 2018; 29: 1180–1188.

[8] Ma L, Zhang Y, Shao Y, Luo L, Zhou J, Wu J, et al. Prognostic significance of systemic inflammatory response markers NLR, PLR, and MLR in advanced high-risk endometrial cancer following radiotherapy. American Journal of Cancer Research. 2025; 15: 966–975.

[9] Akyol D, Özcan FG. The effect of preoperative laboratory values on prognostic factors following cytoreduction surgery in ovarian cancer: neutrophil lymphocyte ratio, platelet lymphocyte ratio, and lymphocyte monocyte ratio. Medicine. 2025; 104: e41504.

[10] Xu W, Liu J, Liu Q, Xu J, Zhou L, Liang Z, et al. NFE2 driven neutrophil polarization promotes pancreatic cancer liver metastasis progression. Cell Reports. 2025; 44: 115226.

[11] Sabit H, Arneth B, Abdel-Ghany S, Madyan EF, Ghaleb AH, Selvaraj P, et al. Beyond cancer cells: how the tumor microenvironment drives cancer progression. Cells. 2024; 13: 1666.

[12] Leng J, Wu F, Zhang L. Prognostic significance of pretreatment neutrophil-to lymphocyte ratio, platelet-to-lymphocyte ratio, or monocyte-to lymphocyte ratio in endometrial neoplasms: a systematic review and meta-analysis. Frontiers in Oncology. 2022; 12: 734948.

[13] Kumari B, Haldar D, Singh GR, Kumari S, Pankaj S, Prasad R. Diagnostic, prognostic, and predictive importance of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and CA125 in endometrial hyperplasia and carcinoma. Indian Journal of Pathology and Microbiology. 2024; 67: 581–584.

[14] Aoyama T, Takano M, Miyamoto M, Yoshikawa T, Kato K, Sakamoto T, et al. Pretreatment neutrophil-to-lymphocyte ratio was a predictor of lymph node metastasis in endometrial cancer patients. Oncology. 2019; 96: 259–267.

[15] Cummings M, Merone L, Keeble C, Burland L, Grzelinski M, Sutton K, et al. Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival. British Journal of Cancer. 2015; 113: 311–320.

[16] Nishio S, Murotani K, Yamagami W, Suzuki S, Nakai H, Kato K, et al. Pretreatment systemic inflammatory markers predict survival in endometrial cancer: a Japanese gynecologic oncology group 2043 exploratory data analysis. Gynecologic Oncology. 2024; 181: 46–53.

[17] Ni L, Tao J, Xu J, Yuan X, Long Y, Yu N, et al. Prognostic values of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in endometrial cancer: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics. 2020; 301: 251–261.

[18] Ronsini C, Iavarone I, Braca E, Vastarella MG, Della Corte L, Vitale C, et al. Deep myometrial infiltration leads to a measurable inflammatory response in endometrial cancer. A prospective observational study. Seminars in Oncology. 2024; 51: 149–153.

[19] Yanazume S, Nagata C, Kobayashi Y, Fukuda M, Mizuno M, Togami S, et al. Potential prognostic predictors of treatment with immune checkpoint inhibitors for advanced endometrial cancer. Japanese Journal of Clinical Oncology. 2025; 55: 29–35.

[20] Lindemann K, Kildal W, Kleppe A, Tobin KAR, Pradhan M, Isaksen MX, et al. Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer. European Journal of Cancer. 2024; 200: 113584.

[21] Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Advances in Anatomic Pathology. 2017; 24: 311–335.

[22] Caruso RA, Bellocco R, Pagano M, Bertoli G, Rigoli L, Inferrera C. Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Modern Pathology. 2002; 15: 831–837.

[23] Dong Y, Cheng Y, Wang J. The ratio of neutrophil to lymphocyte is a predictor in endometrial cancer. Open Life Sciences. 2019; 14: 110–118.

[24] Barrington DA, Calo C, Baek J, Brown M, Wagner V, Gonzalez L, et al. Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy. Gynecologic Oncology. 2022; 166: 522–529.

[25] Ethier JL, Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecologic Oncology. 2017; 145: 584–594.

[26] Njoku K, Ramchander NC, Wan YL, Barr CE, Crosbie EJ. Pre-treatment inflammatory parameters predict survival from endometrial cancer: a prospective database analysis. Gynecologic Oncology. 2022; 164: 146–153.

[27] Li J, Lin J, Luo Y, Kuang M, Liu Y. Multivariate analysis of prognostic biomarkers in surgically treated endometrial cancer. PLOS ONE. 2015; 10: e0130640.

[28] Kimyon Cömert G, Türkmen O, Kar İ, Sınacı S, Yılmaz Ergani S, Karalök A, et al. Independent predictors of survival in endometrium cancer: platelet-to-lymphocyte ratio and platelet/neutrophil/monocyte-to-lymphocyte ratio. Journal of the Turkish-German Gynecological Association. 2018; 19: 78–86.

[29] Nie Y, Yang L, Zhang Y, Guo H. CD8+CD28+PD1− T Cells as a Prognostic Biomarker in Endometrial Cancer. Current Oncology. 2025; 32: 121.

[30] Jungen SH, Noti L, Christe L, Galvan JA, Zlobec I, Müller MD, et al. Spatial distribution of CD3- and CD8-positive lymphocytes as pretest for POLE wild-type in molecular subgroups of endometrial carcinoma. Frontiers in Medicine. 2023; 10: 1110529.

[31] Ahuja S, Dubey A, Zaheer S. Association of stromal tumor infiltrating lymphocytes with clinicopathological parameters in endometrial cancer. Korean Journal of Clinical Oncology. 2024; 20: 74–78.

[32] Guo F, Dong Y, Tan Q, Kong J, Yu B. Tissue infiltrating immune cells as prognostic biomarkers in endometrial cancer: a meta-analysis. Disease Markers. 2020; 2020: 1805764.

[33] Albertí-Valls M, Olave S, Olomí A, Macià A, Eritja N. Advances in immunotherapy for endometrial cancer: insights into MMR status and tumor microenvironment. Cancers. 2024; 16: 3918.

[34] Margul D, Yu C, AlHilli MM. Tumor immune microenvironment in gynecologic cancers. Cancers. 2023; 15: 3849.

[35] Shia J, Black D, Hummer AJ, Boyd J, Soslow RA. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Human Pathology. 2008; 39: 116–125.

[36] Zakurdaev EI, Bagateliya ZA, Titov KS, Elkhouli E, Chizhikov NP, Kharina DV. The role of tumor-associated neutrophils in early luminal HER2-negative breast cancer progression. Asian Pacific Journal of Cancer Prevention. 2025; 26: 207–213.

[37] Dakal TC, George N, Xu C, Suravajhala P, Kumar A. Predictive and prognostic relevance of tumor-infiltrating immune cells: tailoring personalized treatments against different cancer types. Cancers. 2024; 16: 1626.

[38] Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. Journal of Clinical Oncology. 2009; 27: 4709–4717.

[39] Zhao B, Wang S, Xue L, Wang Q, Liu Y, Xu Q, et al. EFHD1 expression is correlated with tumor-infiltrating neutrophils and predicts prognosis in gastric cancer. Heliyon. 2023; 9: e21062.

[40] Sturgeon R, Goel P, Singh RK. Tumor associated neutrophils in pancreatic cancer progression and metastasis. American Journal of Cancer Research. 2023; 13: 6176–6189.

[41] Matsumoto Y, Mabuchi S, Kozasa K, Kuroda H, Sasano T, Yokoi E, et al. The significance of tumor-associated neutrophil density in uterine cervical cancer treated with definitive radiotherapy. Gynecologic Oncology. 2017; 145: 469–475.

[42] Bredin HK, Krakstad C, Hoivik EA. PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: a systematic review and meta-analysis. PLOS ONE. 2023; 18: e0283203.

[43] Niu N, Shen X, Zhang L, Chen Y, Lu P, Yang W, et al. Tumor cell-intrinsic SETD2 deficiency reprograms neutrophils to foster immune escape in pancreatic tumorigenesis. Advanced Science. 2023; 10: e2202937.

[44] López-Janeiro Á, Ruz-Caracuel I, Ramón-Patino JL, De Los Ríos V, Villalba Esparza M, Berjón A, et al. Proteomic analysis of low-grade, early-stage endometrial carcinoma reveals new dysregulated pathways associated with cell death and cell signaling. Cancers. 2021; 13: 794.

[45] López-Janeiro Á, Villalba-Esparza M, Brizzi ME, Jiménez-Sánchez D, Ruz-Caracuel I, Kadioglu E, et al. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients. The Journal of Pathology. 2022; 258: 426–436.